As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629].
Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712].
The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved.